Drs Verona Botha and Ammar Binsadiq have joined Associate Professor James McKelvie at his Waikato-based clinic Eye Surgeons, to accommodate growing demand from population growth and shifting demographics.
What is expected to be permanent Pharmac funding of Ilevro, a non-steroidal anti-inflammatory drop for post-cataract surgery patients, has been welcomed by New Zealand eyecare professionals.
Rayner, a global manufacturer of cataract surgery products, has launched a world-first spiral intraocular lens (IOL) designed using artificial intelligence (AI): RayOne Galaxy and Galaxy Toric.
Following data revealing patient complaints jump significantly with increasing age of their doctor, the Medical Board of Australia (MBA) is considering regular health checks for medical practitioners over 70 years old.
One-year study results from the phase 3 Essence-2 open-label extension (OLE) study for cyclosporine ophthalmic solution 0.1% (Vevye) have shown sustained safety and efficacy in treating the signs and symptoms of dry eye disease (DED).
Dry eye disease (DED) is a highly prevalent condition that affects an estimated one in five adults1. However, early and accurate diagnosis of DED remains a clinical challenge as existing tests are invasive, time-consuming and inaccurate.
An Italian study showed that two sessions of low-level light therapy (LLLT) performed before and after cataract surgery were effective in ameliorating tear film stability and ocular discomfort symptom
Azura Ophthalmics announced the first patient has been enrolled in its phase 3 study to assess the efficacy and safety of AZR-MD-001 ointment in patients with clinical signs and symptoms of meibomian
Zeiss is celebrating a refractive landmark of more than 10 million myopic or astigmatic eyes treated with Zeiss SMILE (small incision lenticule extraction) and Zeiss SMILE pro. Launched in Aus
Blepharitis is a common, underdiagnosed and often untreated eye affliction which may cause a range of clinical manifestations, including irritated eyelid margins, loss of eyelashes, tear film disruption, ocular discomfort and meibomian gland dysfunction1. Causes can include bacterial, viral, fungal
Aldeyra Therapeutics announced it has completed enrolment for its new phase 3 clinical trial of topical ocular 0.25% reproxalap, an investigational RASP modulator for the treatment of dry eye disease.
A Chinese study found continued outdoor exposure to sunlight of an intensity of more than 2,000 lux for at least 15 minutes was associated with less myopic shift in schoolchildren. Writing in JAM
